Appili Therapeutics Inc experienced a remarkable surge in its stock price, closing up 50% in yesterday's trading session.
In a notable turn of events, Appili Therapeutics Inc (APLI.TO) saw its stock price soar by 50% yesterday, closing at CA$0.01. This impressive gain comes amid ongoing developments in the company's operational landscape, particularly in the U.S. market.
Advertisement
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$661,830
52W high
$0.03
52W low
$0.01
1W change
-50.00%
Beta
-0.19
Analyst Price Targets
Based on analyst covering APLI · as of Sep 17, 2026
Wall Street analysts forecast APLI stock price to rise 2900.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+2900.0% Upside
Current Price
C$0.01
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
473.3%
Annualized
90-Day Vol
313.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.00
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.00 | C$0.00 – C$0.02 |
| 60 trading days | C$0.00 | C$0.00 – C$0.04 |
| 90 trading days | C$0.00 | C$0.00 – C$0.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on Appili's commercial progress and funding developments, as these factors could significantly impact future stock performance.
Appili Therapeutics Inc Stock Climbs 50%
The stock's remarkable increase highlights investor optimism surrounding Appili's future prospects and recent operational achievements.
Bull case
The recent surge may show that investors are becoming more confident in Appili's potential. This is especially true given the positive commercial momentum for LIKMEZ® and the substantial funding awards supporting its projects.
Bear case
Despite the positive move, investors should be cautious. Appili's market cap is still relatively low, and the company has yet to establish consistent profitability.
Advertisement
A Closer Look at Appili's Performance
Appili's stock performance yesterday reflects a significant uptick in investor interest, likely driven by the company's recent announcements about its fiscal year financial results. The reported commercial momentum for LIKMEZ® in the U.S. market has positioned Appili favorably, attracting attention from potential investors. For more details on the company's performance, check out our Appili Therapeutics Inc stock page.
Future Prospects and Challenges
While the 50% gain is a positive indicator, investors should consider the broader context of Appili's operations. The company's market cap remains modest, and it has yet to achieve profitability. As such, ongoing developments, including funding and market adoption of its products, will be crucial for sustaining this momentum. Learn more about the potential risks and rewards on our Appili Therapeutics Inc stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
